1. Home
  2. RFI vs NGNE Comparison

RFI vs NGNE Comparison

Compare RFI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Total Return Realty Fund Inc.

RFI

Cohen & Steers Total Return Realty Fund Inc.

HOLD

Current Price

$11.68

Market Cap

303.9M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$30.55

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFI
NGNE
Founded
1992
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.9M
327.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RFI
NGNE
Price
$11.68
$30.55
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$63.57
AVG Volume (30 Days)
74.0K
165.1K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
8.25%
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.78
$13.93
52 Week High
$12.18
$37.27

Technical Indicators

Market Signals
Indicator
RFI
NGNE
Relative Strength Index (RSI) 56.26 68.67
Support Level $10.83 $19.40
Resistance Level $11.72 $32.02
Average True Range (ATR) 0.16 2.05
MACD 0.01 0.36
Stochastic Oscillator 70.15 70.75

Price Performance

Historical Comparison
RFI
NGNE

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: